Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

State of Alaska Department of Revenue cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 25.6% during the 4th quarter, according to the company in its most ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

In this article, we will discuss the 12 Best Healthcare Stocks to Buy According to Analysts. McKinsey reported that, since ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...